Idiopathic Pulmonary Fibrosis: KOL Insight
Roche’s Esbriet, (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) are the only approved therapies for Idiopathic Pulmonary Fibrosis (IPF). Will either be able to establish themselves as first choice, and what future developments could unlock the market?
Idiopathic Pulmonary Fibrosis: KOL Insight critically examines this therapeutic area through the expert insights of 12 leading US and European Key Opinion Leaders. This comprehensive report presents business-critical analysis for the pharma and drug discovery community and reveals what influences prescribing decisions and how clinicians see pipeline products changing the future treatment paradigm for IPF.
Is combination therapy the way of the future for Idiopathic Pulmonary Fibrosis?
Gain KOL insights on key topics such as the combination therapies that could work, the clinical trials that are needed, as well as how drug development and diagnostic players could grow or enter this market sector that has high levels of clinical unmet need.
Gain Answers to Critical Questions
Pipeline Therapies:
North America
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
Idiopathic Pulmonary Fibrosis: KOL Insight critically examines this therapeutic area through the expert insights of 12 leading US and European Key Opinion Leaders. This comprehensive report presents business-critical analysis for the pharma and drug discovery community and reveals what influences prescribing decisions and how clinicians see pipeline products changing the future treatment paradigm for IPF.
Is combination therapy the way of the future for Idiopathic Pulmonary Fibrosis?
Gain KOL insights on key topics such as the combination therapies that could work, the clinical trials that are needed, as well as how drug development and diagnostic players could grow or enter this market sector that has high levels of clinical unmet need.
Gain Answers to Critical Questions
- How can Roche leverage growing evidence of Esbriet’s mortality benefit for wider prescribing?
- What competitive advantage does the once-daily dosing regimen of Boehringer Ingelheim’s Ofev provide?
- What are the key patient characteristics that determine a clinician’s decision to prescribe Esbriet or Ofev, and what lessons are there for Roche, Boehringer Ingelheim and companies developing new pipeline therapies?
- Esbriet and Ofev in combination – is it likely, desirable, or are the risks to patient safety too high?
- How might the development of biomarkers change prescribing choices, and what challenges do developers face?
- Pricing is a contentious issue limiting, in some cases, patient access – what can be done?
- KOLs are cautiously enthusiastic about the prospects of Fibrogen’s FG-3019, Gilead’s simtuzumab and Biogen STX-100 – why, and what insights could influence these company’s research efforts?
- Know the clinical opinions of KOLs and formulate effective strategies for product positioning, clinician communication and patient support
- Review KOL attitudes to important clinical trials such as ASCEND, INPULSIS 1&2, TOMORROW, RAINIER, ATLAS
- Map treatment options to IPF patient sub-groups and know why and when a particular therapy is chosen
- Identify product and patient characteristics that the KOLs think are the most important in terms of prescribing decisions
- Discover which novel pipeline products and combination trials KOLs believe could have a significant impact, and understand the implications for clinical trial design
- Understand why KOLs see combination therapy as the way to progress
Pipeline Therapies:
- Biogen, STX-100
- Bristol-Myers Squibb, BMS-986020
- FibroGen, FG-3019
- Gilead, simtuzumab
- MedImmune/AstraZeneca, tralokinumab
- Roche, lebrikizumab
- Boehringer Ingelheim, Ofev (nintedanib)
- Roche, Esbriet (pirfenidone)
North America
- Dr Harold Collard, University of California San Francisco, California
- Dr Joseph A Lasky, Tulane University, Louisiana
- Dr David Lederer, Columbia University, New York
- Professor Steven D Nathan, Inova Fairfax Hospital, Virginia
- Professor Jesse Roman, University of Louisville, Kentucky
- Professor Victor J Thannickal, University of Alabama at Birmingham, Alabama
- Professor Bruno Crestani, Hopital Bichat Paris, France
- Professor Roland M du Bois, Imperial College London, UK
- Dr Maria Molina-Molina, Bellvitge University Hospital, Spain
- Anonymous KOL, Germany
- Anonymous KOL, Germany
- Anonymous KOL, Germany
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
- Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, May 2015.
- You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.
1. EXECUTIVE SUMMARY
2. RESEARCH OBJECTIVES
3. RESEARCH FOCUS
4. CURRENT TREATMENTS
5. OVERVIEW
6. MARKETED DRUGS
7. ESBRIET (PIRFENIDONE; ROCHE)
8. OFEV (NINTEDANIB; TAKEDA)
9. PIPELINE DRUGS
10. OVERVIEW
11. FG-3019 (FIBROGEN)
12. SIMTUZUMAB (GILEAD)
13. ANTI-IL-13 ANTIBODIES (ROCHE’S LEBRIKIZUMAB AND ASTRAZENECA’S TRALOKINUMAB)
14. STX-100 (BIOGEN)
15. BMS-986020 (BRISTOL-MYERS SQUIBB)
16. FUTURE DEVELOPMENTS IN IPF
17. CURRENT AND FUTURE TREATMENT ALGORITHM
18. CONCLUSION
19. APPENDIX L KOL BIOGRAPHIES
2. RESEARCH OBJECTIVES
3. RESEARCH FOCUS
4. CURRENT TREATMENTS
5. OVERVIEW
6. MARKETED DRUGS
7. ESBRIET (PIRFENIDONE; ROCHE)
8. OFEV (NINTEDANIB; TAKEDA)
9. PIPELINE DRUGS
10. OVERVIEW
11. FG-3019 (FIBROGEN)
12. SIMTUZUMAB (GILEAD)
13. ANTI-IL-13 ANTIBODIES (ROCHE’S LEBRIKIZUMAB AND ASTRAZENECA’S TRALOKINUMAB)
14. STX-100 (BIOGEN)
15. BMS-986020 (BRISTOL-MYERS SQUIBB)
16. FUTURE DEVELOPMENTS IN IPF
17. CURRENT AND FUTURE TREATMENT ALGORITHM
18. CONCLUSION
19. APPENDIX L KOL BIOGRAPHIES
